
    
      This is a postmarket medical device study. This study will examine treatment outcomes for
      patients with TRD who are randomized to VNS Therapy administered at different amounts of
      electrical charge. The Sponsor, Cyberonics, provides funding for this study. Patients are
      followed for 54 weeks, 50 of those weeks are following implantation of the VNS Therapy
      system. No study sites will be permitted to enroll study subjects until Institutional Review
      Board (IRB) approval has been received. Sites are permitted to be approved by a local or a
      central IRB.
    
  